Babraham Institute

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.

Kidger AM, Sipthorp J, Cook SJ

Pharmacology & therapeutics
1879-016X: (2018)

PMID: 29454854

De-RSKing ERK - regulation of ERK1/2-RSK dissociation by phosphorylation within a disordered motif.

Kidger AM, Cook SJ

The FEBS journal
285 1742-4658:42-45 (2018)

PMID: 29314599

Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release.

Dautova Y, Kapustin AN, Pappert K

Journal of molecular and cellular cardiology
1095-8584: (2017)

PMID: 29274344

ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.

Darling NJ, Balmanno K, Cook SJ

PloS one
12 1932-6203:e0184907 (2017)

PMID: 28931068

Control of cell death and mitochondrial fission by ERK1/2 MAP Kinase signalling.

Cook SJ, Stuart K, Gilley R

The FEBS journal
1742-4658: (2017)

PMID: 28548464

Visualisation of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.

Sipthorp J, Lebraud H, Gilley R

Bioconjugate chemistry
1520-4812: (2017)

PMID: 28449575

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608

Maternal DNA Methylation Regulates Early Trophoblast Development.

Branco MR, King M, Perez-Garcia V

Developmental cell
36 1878-1551:152-63 (2016)

PMID: 26812015

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD

Nature reviews. Cancer
15 1474-1768:577-92 (2015)

PMID: 26399658

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M

Cellular and molecular life sciences : CMLS
1420-9071: (2015)

PMID: 26346493

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.

Najas S, Arranz J, Lochhead PA

EBioMedicine
2 2352-3964:120-34 (2015)

PMID: 26137553

Life Sciences Research for Lifelong Health